ACC.17

Anticoagulants Compared in A-fib Patients Undergoing Catheter Ablation

By March 20, 2017

Study patients were randomized to Pradaxa 150mg twice daily or warfarin (target INR 2-3) and remained on this treatment for the trial duration.

Does Lowering LDL with Evolocumab Impact Cognitive Function?

By March 20, 2017

Results showed a similar change in baseline raw score of spatial working memory strategy index of executive function in the evolocumab and placebo groups (mean change from baseline -0.2 vs. -0.3, respectively).

Most Rxs for PCSK9 Inhibitors Initially Rejected, Study Finds

By March 20, 2017

The study researchers evaluated 45,029 new PCSK9 inhibitor prescription claims in one retrospective study.

Guidelines Differ on Recommendations for Statin Tx in African-Americans

March 20, 2017

More African-Americans at high risk of CV events eligible for statin therapy under ACC/AHA guidelines

Antihypertensive Drug Use Has Doubled in Past 20 Years

By March 19, 2017

During the past 2 decades, the use of antihypertensive drug use has "increased remarkably," noted Jens Sundboll, of Aarhus University Hospital, Aarhus, Denmark

Adverse Outcomes Compared for Bivalirudin, Unfractionated Heparin in PCI

By March 19, 2017

When compared to bivalirudin, higher bleeding complications and all-cause mortality were seen with unfractionated heparin among patients undergoing PCI.

Higher Bleeding Risk, Early Antiplatelet Cessation Seen in CKD Patients

By March 19, 2017

Although MI is known to be common among patients with CKD, not much is known about the incidence of post-MI bleeding and premature P2Y12 inhibitor therapy cessation among these patients.

Sacubitril/Valsartan Effective in Ischemic, Non-Ischemic Cardiomyopathy

By March 19, 2017

Study authors reported that sacubitril/valsartan was effective in both ischemic and non-ischemic cardiomyopathy, including the major subgroups of non-ischemic etiology.

Cangrelor Reduces Early MI Events After PCI Initiation

By March 19, 2017

Patients undergoing PCI were randomized at the time of angiography to receive either cangrelor or clopidogrel.

VTE Risk Reduction for Betrixaban vs. Enoxaparin in Post-Parenteral Period

By March 19, 2017

Extended use of betrixaban beyond the usual period of parenteral prophylaxis with enoxaparin reduced venous thromboembolism (VTE) incidence among medically ill patients.

Anti-Arrhythmics Compared for Preventing Post-Op Supraventricular Arrhythmias

By March 19, 2017

Researchers aimed to compare the efficacy of sotalol to other drugs used to prevent arrhythmias (eg, beta-blockers, amiodarone).

Empagliflozin Lowers Risk of Hospitalization, CV Death in HF Patients

By March 19, 2017

Risk reductions in composite outcomes of hospitalization for heart failure (HHF) and modes of cardiovascular (CV) death observed with empagliflozin were comparable to the reduction in the pre-specified composite of HHF or CV death in the EMPAG-REG OTUCOME trial

Does Platelet Count Affect Folic Acid Efficacy in Reducing Stroke Risk?

By March 19, 2017

The efficacy of folic acid supplementation on the risk of stroke was greatest in the lowest quartile of platelet count among hypertensive adults.

Vit D Deficiency: A Risk Factor for ACS and Severe CAD?

By March 19, 2017

Study data found vitamin D to be an important risk factor for acute coronary syndrome (ACS) and severe coronary artery disease (CAD).

IV Amiodarone Reduces A-fib Incidence Post-Esophagectomy

By March 19, 2017

Prophylactic IV amiodarone lowered the incidence of atrial fibrillation (AF) after esophagectomy but was associated with several adverse effects post-esophagectomy.

Real-World Efficacy of Spironolactone in Hospitalized HFrEF Patients

By March 19, 2017

Among eligible patients with heart failure and reduced ejection fraction (HFrEF), use of spironolactone was associated with improved clinical outcomes.

Cangrelor vs. Clopidogrel for Reducing Ischemic Complications During PCI

By March 19, 2017

The safety and efficacy of cangrelor was studied in a subgroup of patients taking unfractionated heparin for PCI in the modified intent-to-treat (mITT) population of the CHAMPION PHOENIX trial.

CV Benefits, Risks Compared for Three Antidiabetic Classes

By March 19, 2017

The network meta-analysis to compare the effects on CV outcomes among 3 major antidiabetic drug classes: DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors.

Stroke, Major Bleeding Risk Low with Dabigatran Etexilate

By March 19, 2017

The data represents ~3,000 patients who had received the study drug in Phase 3 of GLORIA-AF with up to 2 years follow-up.

Furosemide May Increase Fracture Risk in Children with CHD

By March 18, 2017

Clinicians who treat patients with heart disease should be aware of the increased risk of fractures and screen for bone disease in this patient population.

Ezetimibe May Not Help All ASCVD Patients Reach LDL-C Goal

By March 18, 2017

Patients were current statin users and had an LDL-C ≥70mg/dL, they were considered to have reached goal if they achieved an LDL-C level of less than 70mg/dL after 3 months of ezetimibe treatment.

PCSK9 Inhibitors Show Benefit for High-Risk Patients

March 18, 2017

Evolocumab and inclisiran inhibit proprotein convertase subtilisin-kexin type 9.

Mortality Benefit Seen With Statins in Patients with Vasospastic Angina

By March 18, 2017

While considered a standard treatment for atherosclerotic cardiovascular disease, the benefits of statins in patients with vasospastic angina were still an unknown.

Are the Benefits of Oral Anticoagulation Reduced in Frail AF Patients?

By March 18, 2017

At baseline, among 9722 patients with AF, frailty (defined by the American Geriatric Society Criteria) was identified in 5.9% of patients.

Amiodarone Compared to Beta Blockers for Reducing Post-Op AFib

By March 18, 2017

Treatment to prevent post-operative AF in patients undergoing cardiac surgery continues to be controversial.

Major Bleeding Costs Compared for Direct Oral Anticoagulants

By March 18, 2017

The researchers searched the U.S. Medicare database for NVAF patients 65 years of age and older who were newly prescribed one of the following medications: apixaban, dabigatran, rivaroxaban, or warfarin.

Marijuana Use May Up ACS Risk in Younger Adults

By March 18, 2017

There was a significant increase in ACS incidence within the 18-36 year old group.

Mortality Risk and Beta-Blockers Post-ACS: Impact of LV Function

By March 18, 2017

Study authors aimed to evaluate the association between beta-blocker use and all-cause mortality in patients presenting with ACS based on the presence or absence of significant LV dysfunction.

Case: Complete Heart Block Linked to BPH Dietary Supplement

By March 18, 2017

The patient was brought to the emergency department (ED) after complaining of abdominal and chest pain that came on suddenly without exertion.

Exercise May Benefit Patients with Hypertrophic Cardiomyopathy

March 18, 2017

Moderate-intensity exercise linked to increase in exercise capacity at 16 weeks versus usual activity